Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study.
- Danese S IRCCS istituto clinico Humanitás, Humanitas University , Milan , Italy.
- Hart A St Mark's Hospital , Harrow, Middlesex , UK.
- Dignass A Department of Medicine I , Agaplesion Markus Hospital, Goethe-University , Frankfurt/Main , Germany.
- Louis E CHU de Liège , Liège , Belgium.
- D'Haens G Academic Medical Centre , Amsterdam , The Netherlands.
- Dotan I IBD Center, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine , Tel Aviv , Israel.
- Rogler G Division of Gastroenterology and Hepatology , University Hospital Zurich , Zurich , Switzerland.
- D'Agay L Ferring Pharmaceuticals , St Prex , Switzerland.
- Iannacone C McCann Complete Medical , Milan , Italy.
- Peyrin-Biroulet L Department of Gastroenterology and Inserm u954 , Lorraine University , Nancy , France.
- 2016-05-31
Published in:
- BMJ open gastroenterology. - 2016
English
INTRODUCTION
A study has been developed to assess the use and effectiveness of budesonide MMX for mild-to-moderate active ulcerative colitis (UC) in routine clinical practice.
METHODS AND ANALYSIS
A prospective, multicentre, observational, cohort study of 300 patients prescribed budesonide MMX for the treatment of mild-to-moderate active UC will be conducted in Europe, Israel and Canada. Patients will be treated with budesonide MMX9 mg daily for induction of remission for ≤8 weeks. Data on effectiveness, including patient-reported outcomes, tolerability and use will be recorded at the end of treatment and at ≥2 weeks after. The primary outcome (improvement ≥3 point in the clinical subscores of the UC Disease Activity Index score at the end of treatment) will be compared in: patients who receive budesonide MMX added to mesalazine >2 weeks after increased/optimised mesalazine dose for the treatment of flare (late add-on); patients who receive budesonide MMX added to mesalazine ≤2 weeks since mesalazine increased/optimised for the treatment of flare, or without mesalazine dose modification (early add-on); and patients who receive budesonide MMX as monotherapy for the treatment of flare (mono). Propensity scoring will be used to minimise bias and confounding inherent in observational studies.
ETHICS AND DISSEMINATION
First ethical approval: Ethikkommission der Ärztekammer Hamburg (12/22/2015). The results will be published in full.
DISCUSSION
Completion of primary data collection is expected in December 2017. Our results will provide further evidence on the effectiveness of budesonide MMX to support clinicians in their daily practice and inform therapeutic guidelines.
TRIAL REGISTRATION NUMBER
NCT02586259.
A study has been developed to assess the use and effectiveness of budesonide MMX for mild-to-moderate active ulcerative colitis (UC) in routine clinical practice.
METHODS AND ANALYSIS
A prospective, multicentre, observational, cohort study of 300 patients prescribed budesonide MMX for the treatment of mild-to-moderate active UC will be conducted in Europe, Israel and Canada. Patients will be treated with budesonide MMX9 mg daily for induction of remission for ≤8 weeks. Data on effectiveness, including patient-reported outcomes, tolerability and use will be recorded at the end of treatment and at ≥2 weeks after. The primary outcome (improvement ≥3 point in the clinical subscores of the UC Disease Activity Index score at the end of treatment) will be compared in: patients who receive budesonide MMX added to mesalazine >2 weeks after increased/optimised mesalazine dose for the treatment of flare (late add-on); patients who receive budesonide MMX added to mesalazine ≤2 weeks since mesalazine increased/optimised for the treatment of flare, or without mesalazine dose modification (early add-on); and patients who receive budesonide MMX as monotherapy for the treatment of flare (mono). Propensity scoring will be used to minimise bias and confounding inherent in observational studies.
ETHICS AND DISSEMINATION
First ethical approval: Ethikkommission der Ärztekammer Hamburg (12/22/2015). The results will be published in full.
DISCUSSION
Completion of primary data collection is expected in December 2017. Our results will provide further evidence on the effectiveness of budesonide MMX to support clinicians in their daily practice and inform therapeutic guidelines.
TRIAL REGISTRATION NUMBER
NCT02586259.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1136/bmjgast-2016-000092
- PMID 27239329
- Persistent URL
- https://sonar.ch/global/documents/263490
Statistics
Document views: 30
File downloads:
- Full-text: 0